Gilead Sciences, Inc. (BVMF:GILD34)

Market Cap	861.07B
Revenue (ttm)	155.02B
Net Income (ttm)	43.22B
Shares Out	n/a
EPS (ttm)	34.23
PE Ratio	19.92
Forward PE	15.00
Dividend	5.85 (1.69%)
Ex-Dividend Date	Dec 12, 2025

Volume	4
Average Volume	291
Open	351.39
Previous Close	347.00
Day's Range	349.99 - 351.39
52-Week Range	273.00 - 351.39
Beta	0.33
RSI	64.15
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: GILD34

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD